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Purpose: This study aimed to compare health-care utilization and costs in patients treated with long-acting (LA)
vs. short-acting (SA) antiepileptic drug (AED) monotherapy.
Methods:We conducted a cross-sectional study of claims from the OptumInsight™ database. Our analysis was
restricted to adults diagnosed with epilepsy and who used AED monotherapy. Patients were excluded if they
used N1 type of AED, had b9 months of treatment, or had a treatment gap of N60 days. Antiepileptic drugs
were classiﬁed as LA or SA based on published data and expert opinion. Medical and pharmacy claims were
used to estimate health-care utilization and costs, and baseline group differences were adjusted using multivar-
iate analyses.
Results: There were 4058 (49.6%) LA AED users and 4122 (50.4%) SA AED users. Medication possession ratios
(MPRs) were not signiﬁcantly different between LA AED users and SA AED users (P= 0.125). Long-acting AED
users had lower mean overall health-care costs ($9757 vs. $12,689), lower epilepsy-related costs ($3539 vs.
$5279), and lower rate of overall (8.8% vs. 10.9%) and epilepsy-related hospitalizations (5.7% vs. 7.6%) compared
with SA AED users (all P b 0.01). After adjusting for demographics and clinical characteristics, mean overall costs
were lower by $686 and the mean epilepsy-related costs were lower by $894 in LA AED users.
Conclusion: Although MPRs were similar in LA AED and SA AED groups, patients treated with LA monotherapy
had a lower economic burden compared with those treated with SA monotherapy, indicating that using AEDs
with extended duration of action is associated with decreased health-care use and lower health-care costs.© 2014 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy affects approximately 2.2 million Americans [1] and
accounts for an estimated $15.5 billion in direct and indirect costs in
the United States annually [2]. Patients with epilepsy typically require
long-term or lifetime pharmacotherapy, and with more than 20 antiep-
ileptic drugs (AEDs) currently available, the decision-making process
for treatment is increasingly complex [3]. Suboptimal adherence has
been linked to a wide variety of consequences, including increased
rates of seizures, head injuries, and hospitalizations, and is associated
with increased health-care utilization and costs [4–6].
A long-acting (LA) AED will remain in a patient's systemic circula-
tion longer after the last dose compared with a short-acting (SA) AED.
Extended-release drugs are formulated to dissolve and release slowly,Partnership for Health Analytic
, Houston, TX 77027-9310, USA.
r), Jason_Wang@eisai.com
er@eisai.com (R. Copher),
m (M.S. Broder).allowing for less frequent dosing. This property may make longer half-
life or ER drugs more “forgiving” of missed doses, with the reduced
serum medication levels more effectively bridged by drugs with longer
half-lives. If this is the case, then use of longer half-life or extended-
release (ER) formulationsmightmitigate the impact of imperfect adher-
ence. That is, for a given level of adherence, users of longer half-life or ER
drugs might be expected to have better efﬁcacy and lower health-care
utilization and costs compared with users of shorter half-life drugs.
To assesswhether AEDswith extended half-life or longer duration of
action might be associated with improved health and economic
outcomes, we used a large commercial health-care claims database to
compare the extent of health service utilization and costs in adult
patients treated with either LA or SA AED monotherapy.
2. Material and methods
2.1. Study design and data sources
We conducted a cross-sectional study to compare clinical and eco-
nomic outcomes among adult patients using LA or SA AED monothera-
py. Antiepileptic drugs were classiﬁed as LA (thosewith long half-life or
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tion, published data, and expert opinion [7] (see Appendix Table). Long-
acting AEDs included phenytoin ER (PHT ER), carbamazepine ER (CBZ
ER), topiramate (TPM), divalproex ER (DVP ER), divalproex delayed re-
lease (DR) (DVP DR), phenobarbital (PB), levetiracetam ER (LEV ER),
and zonisamide (ZNS). Short-acting AEDs included levetiracetam
(LEV), lamotrigine (LTG), carbamazepine (CBZ), and oxcarbazepine
(OXC).
The study used data from the OptumInsight™ Clinformatics™ Data
Mart database, a commercial Health Insurance Portability and Account-
ability Act (HIPAA)-compliant administrative claims database of rough-
ly 14 million covered lives per year that represents all major regions of
the United States. The OptumInsight database contains deidentiﬁed ad-
judicated pharmacy claims (e.g., outpatient prescriptions) and medical
claims (e.g., inpatient and outpatient services) submitted for payment
by providers, health-care facilities, and pharmacies and includes infor-
mation on each physician visit, medical procedure, hospitalization,
drug dispensed, date of service/prescription, number of days of medica-
tion supplied, and tests performed. Drug-related claims are only record-
ed for the outpatient setting. Pricing data are also included, and these
data are adjusted to account for differences in contracting and other
variations across health plans. These standardized prices are used as
costs in this analysis. Also available are member enrollment and beneﬁt
information as well as limited patient, provider, and hospital demo-
graphic information.
2.2. Study population and study timeframe
We included commercially insured adults (≥18 years old) who
were diagnosed with epilepsy and who were treated with LA or SA
AED monotherapy during the 2011 calendar year (study period).
Patients were included in the study if they had ≥2 medical claims at
least 30 days apart with International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) codes of 345.xx (epilepsy)
or 780.39 (other convulsions) in any diagnosis ﬁeld. In order to exclude
newly diagnosed patients (who might have differed signiﬁcantly from
those receiving ongoing care), one epilepsy claim had to occur during
the study period, and another claim had to occur during the year before
the study period. In addition, patients were required to have had ≥2
pharmacy claims for one of the listed AEDs, both during the study
period.
Patients were excluded from the study if they had more than 1 type
of AED ﬁlled during the study period; if they were not continuously en-
rolled during the 12-month study period and for 3 months before the
study period (used to determine if AEDs were available at the start of
the study period); if they were treated for b9 months or if they had a
treatment gap of N60 days between the end of days of supply and the
next ﬁll date; or if they did not use one of the top 12 most frequently
used AEDs.
2.3. Study measures
Studymeasureswere derived using enrollment ﬁles, medical claims,
and pharmacy claims. The claim database contains every claim for an
individual's period of enrollment.We assumed that therewere nomiss-
ing data because a payment is processed only if a claim exists. We used
all medical and pharmacy claims in the 12-month study period to con-
struct the baseline measures, including patient demographics, AED ad-
herence, specialty of the usual care physician, and burden of illness.
Medical and pharmacy claimswere used to estimate health-care utiliza-
tion and costs, and baseline differences were adjusted using multivari-
ate analysis.
Enrollment recordswere used to identify patient demographic infor-
mation (age, sex, and US census region). Antiepileptic drug adherence
was estimated by the medication possession ratio (MPR), deﬁned as
the total days of therapy available in the study period divided by365 days. Considering this deﬁnition, that MPR summarizes medication
ﬁlls and not actual medication-taking behavior. To calculate the MPR,
we truncated days of supply to exclude AEDs available before, or AED
claims extending after, the study period. Specialty of the usual physician
was deﬁned as the physician specialty with the largest plurality of ofﬁce
visits with evaluation andmanagement (E&M) service codes during the
review period [8]. Specialty was reported as “unknown” if it could not
be identiﬁed with E&M service claims or if it was recorded as “un-
known” on the claim.
Severity of illness was captured by three measures: the Charlson
Comorbidity Index, the number of chronic conditions, and the
epilepsy-speciﬁc comorbidities, all of which were measured during
the study period (2011 calendar year). The Charlson Comorbidity
Index, initially developed as predictor of in-hospital mortality, has
been widely adapted and used to measure overall burden-of-illness in
the general population [9,10]. We used the validated Healthcare Cost
and Utilization Project (HCUP) Chronic Condition Indicator [11,12],
which categorizes ICD-9-CM diagnosis codes as chronic or not chronic,
to count the number of chronic conditions. A chronic condition is de-
ﬁned as a condition that lasts ≥12 months and either (a) places limita-
tions on self-care, independent living, and social interactions or
(b) results in the need for ongoing intervention with medical products,
services, and special equipment [12]. Finally, we identiﬁed epilepsy-
speciﬁc comorbidities that may have complicated the management of
epilepsy or could have caused the disease: head injury, brain tumor, ce-
rebrovascular disease/stroke, meningitis/vasculitides, tuberous sclero-
sis, and depression and other mood disorders.
The main outcome measures were annual health-care utilization
and costs, both overall and epilepsy-related. Measures of health-care
utilization included the number of inpatient hospitalizations, the num-
ber of emergency department (ED) visits, and the number of physician
ofﬁce visits. Epilepsy-relatedutilizationwas deﬁned asAEDprescription
ﬁlls, medical services associated with claims with an epilepsy diagnosis
in any diagnosis ﬁeld, and epilepsy-related tests (AED levels, electro-
encephalography [EEG], and brain imaging studies such as computed
tomography, magnetic resonance imaging, positron emission tomogra-
phy, and single-photon emission computed tomography). Epilepsy-
related costs were deﬁned similarly.
2.4. Statistical analysis
Descriptive statistics, including mean, standard deviation (SD), and
percentage, were reported for all measures, stratiﬁed by treatment co-
hort. The chi-square test and Student's t-testwere used for dichotomous
and continuous variables, respectively. All tests were two-sided with a
signiﬁcance level of 0.05.
We conducted several regression models to study the association
between treatment half-life and outcomes. These included multivariate
models for annual overall and epilepsy-related costs and logistic regres-
sionmodels for the occurrence of inpatient hospitalization (both overall
and epilepsy-related). All models were adjusted for patient and clinical
characteristics as appropriate, including age, sex, US census region,
usual physician specialty, Charlson Comorbidity Index, chronic
conditions, and epilepsy-speciﬁc comorbidities. Data transformations
and statistical analyses were performed using SAS® version 9.3 (SAS
Institute, Cary, NC).
3. Results
We initially identiﬁed 32,705 patients with≥2 epilepsy claims (1 in
2010 and 1 in 2011) from the OptumInsight database. Of these, we ex-
cluded 5736 patients who ﬁlled b2 AED claims in 2011, 4131 whowere
not continuously enrolled between 10/1/2010 and 12/31/2011, 4488
who were b18 years old, and 7653 who were treated with more than
one AED. We also excluded 2087 patients who were treated for b9
months or who had a treatment gap of N60 days and 429 patients
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analytic sample included 8180 adult AED users, of whom 4058 (49.6%)
used LA AEDs and 4122 (50.4%) used SA AEDs.
Table 1 describes patient and physician characteristics of the study
cohort. Long-acting AED users were older and had a lower Charlson
Comorbidity Index score, fewer chronic conditions, and fewer
epilepsy-speciﬁc comorbidities compared with their SA AED counter-
parts, while SA AED users were more commonly female. Long-acting
AED and SA AED users both received their care most frequently from
primary care physicians (52.4% vs. 39.6%, respectively), followed by
neurologists (28.9% vs. 39.5%), and other specialists (18.7% vs. 20.9%).
There was no statistically signiﬁcant difference in AED adherence be-
tween LA AED users and SA AED users, with a mean MPR of 0.899
(SD: 0.13) in LA AED users compared with an MPR of 0.903 (SD: 0.13)
in SA AED users (P= 0.125) (Table 2).
In univariate comparisons of health-care utilization in the study pe-
riod (Table 3), 8.8% of LA AED users had ≥1 inpatient hospitalization
compared with 10.9% of SA AED users (P = 0.003), while 5.7% of LA
AED users had ≥1 epilepsy-related hospitalization compared with
7.6% of SA AED users (P=0.005). Long-acting AED users also had signif-
icantly fewer overall annual ED visits and fewer overall and epilepsy-
related physician ofﬁce visits compared with SA AED users. There was
no difference in the number of epilepsy-related ED visits between LA
AED users and SA AED users (P = 0.343). Long-acting AED users did
have a signiﬁcantly higher rate of testing for AED levels compared
with SA AED users (22.8% of LA AED users were tested ≥1 times vs.
12.7% of SA AED users; P b 0.001), but the percentage of patients who
had ≥1 electroencephalographic (7.4% vs. 12.6%) or brain imaging
study (11.2% vs. 18.0%) was lower in LA AED users than in SA AED
users (all P b 0.001).
Table 4 displays unadjusted costs associated with the treatment of
adult patientswith epilepsy. Annual health-care costswere signiﬁcantly
lower in LA AED users ($9757; SD: $21,634) than in SA AED users per
patient-year ($12,689; SD: $25,358; P b 0.001), a difference of $2932Table 1
Patient demographics, usual physician specialty, and baseline comorbidity measures in adult p
Long-acting AED monotherapy
n = 4058; 49.6%
Age, year, mean (SD) 47.7 (14.5)
Age group, year, n (%)
18–34 811 (20.0)
35–44 762 (18.8)
45–54 1084 (26.7)
55+ 1401 (34.5)
Female, n (%) 1931 (47.6)
Region, n (%)
Midwest 1208 (29.8)
Northeast 411 (10.1)
South 1866 (46.0)
West 573 (14.1)
Usual physician specialty, n (%)
Neurology 1174 (28.9)
Primary careb 2127 (52.4)
Otherc/unknownd 757 (18.7)
Charlson Comorbidity Index, mean (SD) 0.7 (1.5)
Number of chronic conditions, mean (SD) 2.9 (1.8)
Any epilepsy-speciﬁc comorbidities,e n (%) 772 (19.0)
Head injury 16 (0.4)
Brain tumor 93 (2.3)
Cerebrovascular disease/stroke 287 (7.1)
Depression and other mood disorders 429 (10.6)
Meningitis/vasculitides 15 (0.4)
Tuberous sclerosis 8 (0.2)
AED, antiepileptic drug; E&M, evaluation and management; SD, standard deviation.
a Long-acting vs. short-acting AED monotherapy.
b Including family practice, internal medicine, and pediatrics.
c All individual specialties in “Other” are b2%.
d Specialty was reported as “unknown” if it could not be identiﬁed with E&M service claims
e Patients could have more than one comorbidity.reﬂected by $1586 less in medical costs and $1346 less in pharmacy
costs annually (both P ≤ 0.001). Epilepsy-related annual health-care
costs were similarly lower (a difference of $1740) in LA AED
users than in SA AED users ($3539 [SD: 11,077] vs. $5279 [SD:
17,157]; P b 0.001), including $842 less in epilepsy-related medical
costs ($2355 for LA vs. $3197 for SA; P = 0.008) and $898 less in AED
costs ($1184 for LA vs. $2082 for SA; P b 0.001).
After adjusting for baseline demographics, region, usual care physi-
cian specialty, and clinical characteristics, we found that themean over-
all costs were $686 less (standard error [SE]: $460; P=0.137) and that
themean epilepsy-related costswere $894 less (SE: $319; P=0.005) in
LA AED users than in SA AED users (Table 5). The risk of inpatient
hospitalization (odds ratio [OR]: 1.02; 95% conﬁdence interval [CI]:
0.87–1.21) and epilepsy-related inpatient hospitalization (OR: 0.94;
95% CI: 0.78–1.13) were not statistically signiﬁcantly different for
patients who received SA AED monotherapy than for patients who
received LA AED monotherapy. Adjusted costs were greater in SA AED
users than in LA AED users, but this difference was only statistically
signiﬁcant for epilepsy-related costs.
4. Discussion
Suboptimal adherence to medications is a serious problem in chron-
ic illness management. Medication adherence is a complex behavior
and affected by many factors. A recent systematic review identiﬁed
hundreds of factors contributing tomedication adherence or lack there-
of, two of which include dosing frequency and duration of action [13].
Priormedical claims studies have suggested that suboptimalmedication
adherence in epilepsy has been a particularly critical problem [4,14].
Lack of adherence to AEDs has been linked to increased burden of ill-
ness, and previous studies have examined the impact of nonadherence
to AEDs on health-care utilization and costs [4–6].Moreover, education-
al and behavioral interventions to improve adherence to AEDs in
patients with epilepsy have had only mixed results [15]. The lack ofatients with epilepsy.
Short-acting AED monotherapy
n = 4122; 50.4%
All
N = 8180
P valuea
45.1 (16.0) 46.4 (15.3) b0.001
b0.001
1185 (28.7) 1996 (24.4)
820 (19.9) 1582 (19.3)
902 (21.9) 1986 (24.3)
1215 (29.5) 2616 (32.0)
2349 (57.0) 4280 (52.3) b0.001
0.829
1212 (29.4) 2420 (29.6)
443 (10.7) 854 (10.4)
1883 (45.7) 3749 (45.8)
584 (14.2) 1157 (14.1)
b0.001
1628 (39.5) 2802 (34.3)
1632 (39.6) 3759 (46.0)
862 (20.9) 1619 (19.8)
0.8 (1.6) 0.7 (1.6) b0.001
3.1 (2.0) 3.0 (1.9) b0.001
1031 (25.0) 1803 (22.0) b0.001
32 (0.8) 48 (0.6) 0.024
236 (5.7) 329 (4.0) b0.001
399 (9.7) 686 (8.4) b0.001
496 (12.0) 925 (11.3) 0.037
14 (0.3) 29 (0.4) 0.819
10 (0.2) 18 (0.2) 0.661
or if it was recorded as “unknown” on the claim.
Table 2
Antiepileptic drug use and medication possession ratio (MPR).
Long-acting AED monotherapy
n = 4058; 49.6%
Short-acting AED monotherapy
n = 4122; 50.4%
AED No. (%) MPR (0–1) AED No. (%) MPR (0–1)
Mean (SD) [Median] Mean (SD) [Median]
All 4058 (100.0) 0.899a (0.13) [0.953] All 4122 (100.0) 0.903a (0.13) [0.959]
PHT ER 1604 (39.5) 0.902 (0.12) [0.951] LEV 1667 (40.4) 0.902 (0.13) [0.956]
CBZ ER 661 (16.3) 0.908 (0.13) [0.964] LTG 1351 (32.8) 0.910 (0.13) [0.967]
TPM 449 (11.1) 0.877 (0.14) [0.937] CBZ 593 (14.4) 0.898 (0.14) [0.962]
DVP ER 407 (10.0) 0.885 (0.14) [0.942] OXC 511 (12.4) 0.895 (0.14) [0.948]
DVP DR 321 (7.9) 0.879 (0.14) [0.932]
PB 273 (6.7) 0.920 (0.11) [0.973]
LEV ER 191 (4.7) 0.921 (0.11) [0.964]
ZNS 152 (3.7) 0.907 (0.13) [0.967]
AED, antiepileptic drug; ER, extended release; DR, delayed release.
LA AEDs: phenytoin ER (PHT ER); carbamazepine ER (CBZ ER); topiramate (TPM); divalproex ER (DVP ER); divalproex DR (DVP DR); phenobarbital (PB); levetiracetam ER (LEV ER);
zonisamide (ZNS); SA AEDs: levetiracetam (LEV); lamotrigine (LTG); carbamazepine (CBZ); oxcarbazepine (OXC).
a MPRs were not signiﬁcantly different between the two cohorts (P= 0.125).
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tion of action might mitigate the impact of poor adherence on health-
care utilization and costs was the impetus for the current study.
A recent study examined economic outcomes between groups of
adult patients identiﬁed as having stable and uncontrolled epilepsy
[16], but, to our knowledge, this is the ﬁrst study to provide detailed in-
formation on health-care utilization and costs incurred by commercially
insured patientswith epilepsy in theUSwhowere treatedwith LAor SA
AED monotherapy. Using a large administrative claims database, our
study demonstrated that for patients with similar adherence rates,Table 3
Annual overall and epilepsy-related health-care utilization in adult patients with epilepsy.
Long-acting AED monotherap
n = 4058; 49.6%
Annual overall health-care utilization
Inpatient hospitalizations, n (%)
0 3704 (91.3)
1 295 (7.3)
2+ 59 (1.5)
ED visits, n (%)
0 3735 (92.0)
1 156 (3.8)
2+ 167 (4.1)
Ofﬁce visits, mean (SD) [median] 8.8 (9.4)
Annual epilepsy-relatedb health-care utilization
Epilepsy-relatedb inpatient hospitalizations, n (%)
0 3826 (94.3)
1 208 (5.1)
2+ 24 (0.6)
Epilepsy-relatedb ED visits, n (%)
0 4037 (99.5)
1+ 21 (0.5)
Epilepsy-relatedb ofﬁce visits, mean (SD) 1.8 (1.5)
EEG, n (%)
0 3760 (92.7)
1 251 (6.2)
2 28 (0.7)
3+ 19 (0.5)
Brain imaging, n (%)
0 3605 (88.8)
1 349 (8.6)
2 69 (1.7)
3+ 35 (0.9)
AED levels, n (%)
0 3135 (77.3)
1 685 (16.9)
2 177 (4.4)
3+ 61 (1.5)
AED, antiepileptic drug; ED, emergency department; EEG, electroencephalogram; SD, standard
a Long-acting vs. short-acting AED monotherapy.
b Claims with a diagnosis of epilepsy in any diagnosis ﬁeld or epilepsy-related tests.those who were treated with LA AED monotherapy incurred a lower
economic burden compared with those who were treated with SA
monotherapy. This ﬁnding suggests that the use of longer half-life
drugs might mitigate the impact of imperfect adherence. In addition,
LA AED users had a signiﬁcantly lower rate of hospitalization, a lower
mean number of ofﬁce visits compared with SA AED users, and signiﬁ-
cantly lower use of EEG and brain imaging. They had fewer overall ED
visits, but there was no signiﬁcant difference in epilepsy-related ED
visits. The only aspect of resource utilization that was higher in LA
AED users was AED serum level testing. Taken as a whole, these resultsy Short-acting AED monotherapy
n = 4122; 50.4%
All
N = 8180
P valuea
0.003
3676 (89.2) 7380 (90.2)
357 (8.7) 652 (8.0)
89 (2.2) 148 (1.8)
0.009
3724 (90.3) 7459 (91.2)
184 (4.5) 340 (4.2)
214 (5.2) 381 (4.7)
9.9 (10.0) 9.4 (9.7) b0.001
0.005
3812 (92.5) 7638 (93.4)
279 (6.8) 487 (6.0)
31 (0.8) 55 (0.7)
0.343
4094 (99.3) 8131 (99.4)
28 (0.7) 49 (0.6)
2.0 (1.6) 1.9 (1.6) b0.001
b0.001
3602 (87.4) 7362 (90.0)
427 (10.4) 678 (8.3)
51 (1.2) 79 (1.0)
42 (1.0) 61 (0.7)
b0.001
3378 (82.0) 6983 (85.4)
499 (12.1) 848 (10.4)
132 (3.2) 201 (2.5)
113 (2.7) 148 (1.8)
b0.001
3596 (87.2) 6731 (82.3)
381 (9.2) 1066 (13.0)
107 (2.6) 284 (3.5)
38 (0.9) 99 (1.2)
deviation.
Table 4
Annual overall and epilepsy-related health-care costs in adult patients with epilepsy.
Long-acting AED monotherapy
n = 4058; 49.6%
Short-acting AEDmonotherapy
n = 4122; 50.4%
All
N = 8180
P valuea
Mean (SD) Mean (SD) Mean (SD)
Overall health-care costs, $ 9757 (21,634) 12,689 (25,358) 11,234 (23,628) b0.001
Medical cost, $ 6745 (19,984) 8331 (23,557) 7544 (21,870) 0.001
Pharmacy cost, $ 3012 (4891) 4358 (6042) 3690 (5542) b0.001
Epilepsy-related overall health-care costs, $ 3539 (11,077) 5279 (17,157) 4416 (14,489) b0.001
Epilepsy-relatedb medical cost, $ 2355 (10,896) 3197 (17,002) 2779 (14,308) 0.008
AED cost, $ 1184 (1733) 2082 (2412) 1637 (2150) b0.001
PHT ER (n = 1604) $444 (208)
CBZ ER (n = 661) $1419 (759)
TPM (n = 449) $2237 (3563)
DVP ER (n = 407) $1594 (1212)
DVP DR (n = 321) $1440 (1174)
PB (n = 273) $70 (51)
LEV ER (n = 191) $4455 (2231)
ZNS (n = 152) $1114 (1104)
LEV (n = 1667) $2346 (2044)
LTG (n = 1351) $2309 (3097)
CBZ (n = 593) $424 (581)
OXC (n = 511) $2544 (1949)
AED, antiepileptic drug; ED, emergency department; SD, standard deviation.
a Long-acting vs. short-acting AED monotherapy.
b Claims with a diagnosis of epilepsy in any position.
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crease their economic burden and health-care resource utilization by
switching to LA AEDs.
Epilepsy-related annual health-care costs remained signiﬁcantly
lower in LA AED users than in SA AED users after adjusting for demo-
graphics, usual physician specialty, and comorbidities. The overall
health-care cost difference between the LA AED users and the SA AED
users became statistically insigniﬁcant after adjusting for patient and
clinical characteristics; however, the numeric difference points to the
direction of potentially better economic outcomes with LA AED use.
Those ﬁndings are consistent with the ﬁnding that LA AED users also
had a generally lower rate of resource utilization. Epilepsy-related
health-care costs in our study accounted for b40% of total observed
health-care costs, which suggests that comorbid conditions may
be costly and/or that epilepsy-related health-care utilization was
underidentiﬁed. Timely surveillance and treatment of comorbidTable 5
Regression models of overall and epilepsy-related health-care costs and utilization in adult pat
Overall health-care costs Epilepsy-
health-ca
Coefﬁcient (SE) P Coefﬁcien
Age group, year
18–34 vs. 55+ 3476a (666) b0.001 2304a
35–44 vs. 55+ 3224a (685) b0.001 2059a
45–54 vs. 55+ 1283a (621) 0.039 936a
Female vs. male 226 (455) 0.620 82
Region
Midwest vs. West −488 (726) 0.502 124
Northeast vs. West −2065a (918) 0.025 −911
South vs. West −107 (684) 0.876 100
Usual physician specialty
Neurology vs. primary care 2790a (541) b0.001 1764a
Other/unknown vs. primary care 6036a (610) b0.001 1089a
Charlson Comorbidity Index 4543a (173) b0.001 943a
No. of chronic conditions 3460a (156) b0.001 1393a
Any epilepsy-speciﬁc comorbiditiesb 934 (601) 0.121 32
Long-acting vs. short-acting −686 (460) 0.137 −894a
CI, conﬁdence interval; OR, odds ratio; SE, standard error.
a Estimate is statistically signiﬁcantly different from zero.
b Head injury, brain tumor cerebrovascular disease/stroke, depression and other mood disoconditions in adults with epilepsy are important because co-occurring
conditions can be the cause of seizures (e.g., cerebrovascular disease)
or can be exacerbated by epilepsy (e.g., neurodegenerative diseases),
and poor control of comorbidities may further complicate the overall
management of the disease, leading to an increased economic burden
[1,17–20].
4.1. Strengths and limitations
We analyzed a large sample of adult patients with epilepsy identi-
ﬁed in a major commercial insurance claims database representing all
geographic regions of the United States. The availability of this large
dataset allowed us to detect statistically signiﬁcant group differences
in measures of burden-of-illness, health-care utilization, and health-
care costs. The breadth of the claims database allowed us to compare
adult patients whowere treatedwith either LA or SA AEDmonotherapyients with epilepsy.
related overall
re costs
Risk of inpatient
hospitalization
Risk of epilepsy-related
inpatient hospitalization
t (SE) P OR (95% CI) OR (95% CI)
(461) b0.001 1.92a (1.52–2.43) 1.84a (1.41–2.40)
(474) b0.001 1.47a (1.15–1.86) 1.44a (1.09–1.90)
(430) 0.030 0.79a (0.63–1.00) 0.89 (0.68–1.15)
(315) 0.796 1.22a (1.04–1.44) 1.07 (0.89–1.29)
(503) 0.805 0.99 (0.77–1.27) 1.01 (0.76–1.34)
(636) 0.152 0.62a (0.45–0.87) 0.68a (0.47–1.00)
(474) 0.834 0.93 (0.74–1.18) 0.89 (0.68–1.17)
(375) b0.001 1.13 (0.92–1.39) 1.18 (0.93–1.49)
(423) 0.010 1.33a (1.09–1.61) 1.35a (1.08–1.69)
(120) b0.001 1.19a (1.14–1.25) 1.11a (1.06–1.16)
(108) b0.001 1.53a (1.45–1.60) 1.46a (1.38–1.54)
(417) 0.939 1.27a (1.06–1.52) 1.29a (1.05–1.58)
(319) 0.005 1.02 (0.87–1.21) 0.94 (0.78–1.13)
rders, meningitis/vasculitides, and tuberous sclerosis.
45J.A. Cramer et al. / Epilepsy & Behavior 44 (2015) 40–46on a number of key overall and epilepsy-related health-care utilization
and cost measures. We were also able to produce age, gender,
geographic region, and comorbidity-adjusted estimates of epilepsy
cohort differences in health-care utilization and costs.
This study has limitations. Administrative claims databases are
designed for payment, not research. Claims data lack clinical detail, do
not capture disease severity and duration, and do not include the
reasons why certain AEDs were prescribed to a patient. International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation codes
also do not provide information about speciﬁc epilepsy syndromes.
Hence, there could be a variety of unmeasured AED monotherapy
group differences, which we were not able to adjust for in our analyses,
butwhichmay impact outcomes of interest. The claims database includ-
ed only commercially insured patients; thus, the resultsmay not be gen-
eralizable to populations without insurance or other types of coverage.
The use of this database only allowed us to analyze direct costs,
although epilepsy may be associated with considerable social and
emotional burden and their associated indirect costs [1,21–25]. Another
limitation of our study is that MPR summarizes medication ﬁlls, not
actual medication-taking behavior. This study was also not designed
to assess whether costs changed if a patient switched from a SA AED
to a LA AED or vice versa.
Patients who receive LA AED monotherapy accrue lower costs com-
pared with those who receive SA AED monotherapy, indicating that
AEDs with extended duration of action are associated with less health-
care use and decreased economic burden. The higher pharmacy costs
in the SA AED monotherapy patients, however, do not explain the
higher overall costs since medical care costs are also higher in the SA
AED monotherapy patients than in those with LA AED monotherapy.
These ﬁndings support our study hypothesis that the LA AEDs are asso-
ciated with improved health and economic outcomes. This could be the
result of reduced peak-to-trough serum AED ﬂuctuations, improved ad-
herence due to the convenience of less frequent administration, or mit-
igation of imperfect adherence. Future studies should assess the impact
of duration of action on outcomes in combination therapy, as many pa-
tients with epilepsy require more than one AED to achieve optimal dis-
ease control. Patients with uncontrolled epilepsy use more health-care
services and incur higher costs comparedwith thosewith stable epilep-
sy [16]. Future research should examine economic impacts between LA
and SA AED treatment groups while controlling for epilepsy disease
status.
4.2. Conclusion
Commercially insured patients treated with LA monotherapy had a
lower economic burden compared with those treated with SA mono-
therapy, indicating that using AEDs with extended duration of action
was associated with decreased health-care use and lower health-care
costs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yebeh.2014.12.020.
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